other: Dosage & Administration
Usual adult dose is 1 tablet daily, or as directed by a physician.
other: Storage
Store at controlled room temperature 15 degrees-30 degrees C (59 degrees-86 degrees F) [see USP]. Protect from light and moisture and avoid excessive heat. Dispense in a tight, light resistant container as defined by the USP using a child-resistant closure.
warning: Warning: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
other: Quatrefolic is a registered trademark of Gnosis, SpA.
-U.S. Patent No. 7,947,662.
other: Clinical Pharmacology: Iron is an essential component in the formation of hemoglobin. Adequate amounts of iron are necessary for effective erythropoiesis. Iron also serves as a cofactor of several essential enzymes, including cytochromes that are involved in electron transport. Folic acid is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is converted in the liver and plasma to its metabolically active form, tetrahydrofolic acid, by dihydrofolate reductase. Vitamin B12 is required for the maintenance of normal erythropoiesis, nucleoprotein and myelin synthesis, cell reproduction and normal growth. Intrinsic factor, a glycoprotein secreted by the gastric mucosa, is required for active absorption of vitamin B12 from the gastrointestinal tract.
other: Indications and Usage: Corvite 150 is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias.
warning: Contraindications: Corvite 150 is contraindicated in patients with a known hypersensitivity to any of the components of this product. Hemochromatosis and hemosiderosis are contraindications to iron therapy.
Warnings: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin b12 is deficient.
Precautions
General: Do not exceed recommended dose. The type of anemia and the underlying cause or causes should be determined before starting therapy with Corvite 150. Since the anemia may be a result of a systemic disturbance, such as recurrent blood loss, the underlying cause or causes should be corrected, if possible.
Folic Acid: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Pernicious anemia should be excluded before using this product since folic acid may mask the symptoms of pernicious anemia
warning: Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
warning: Geriatric Use: Clinical studies on this product have not been performed in subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious.
Adverse Reactions: Adverse reactions with iron therapy may include constipation, diarrhea, nausea, vomiting, dark stools and abdominal pain. Adverse reactions with iron therapy are usually transient.
warning: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
warning: Overdosage: The clinical course of acute iron overdosage can be variable. Initial symptoms may include abdominal pain, nausea, vomiting, diarrhea, tarry stools melena, hematemesis, hypotension, tachycardia, metabolic acidosis, hyperglycemia, dehydration, drowsiness, pallor, cyanosis, lassitude, seizures, shock and coma.
claim: Description: Corvite 150 are red, oval bisected tablets embossed "VP052."
How Supplied: Corvite 150 tablets are supplied in bottles of 30 units.
Label facts as declared by the manufacturer to the NIH Dietary Supplement Label Database (DSLD), not independently
lab-tested. This page reports what the label says; it does not rate, score, or recommend this product.